Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference newsletter

  Ovarian Neoplasms

  Free Subscription


2 BMC Cancer
21 Gynecol Oncol
1 Int J Cancer
1 Int J Gynaecol Obstet
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BMC Cancer

  1. ESCALONA RM, Bilandzic M, Western P, Kadife E, et al
    TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
    BMC Cancer. 2020;20:960.
    PubMed         Abstract available

  2. HOOVER AA, Hufnagel DH, Harris W, Bullock K, et al
    Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer.
    BMC Cancer. 2020;20:970.
    PubMed         Abstract available

    Gynecol Oncol

  3. CORVIGNO S, Mezheyeuski A, De La Fuente LM, Westbom-Fremer S, et al
    High density of stroma-localized CD11c-positive macrophages is associated with longer overall survival in high-grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 5. pii: S0090-8258(20)33951.
    PubMed         Abstract available

  4. BOGANI G, Ditto A, Lopez S, Bertolina F, et al
    Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Jan 21. pii: S0090-8258(19)31875.
    PubMed         Abstract available

  5. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Primary malignant ovarian carcinoid; management and outcomes.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30002.
    PubMed         Abstract available

  6. CONNOR YD, Miao D, Lin DI, Hayne C, et al
    Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
    Gynecol Oncol. 2019 Dec 21. pii: S0090-8258(19)31618.
    PubMed         Abstract available

  7. LLAURADO FERNANDEZ M, Dawson A, Kim H, Lam N, et al
    Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(19)31680.
    PubMed         Abstract available

  8. MATSUO K, Machida H, Matsuzaki S, Grubbs BH, et al
    Evolving population-based statistics for rare epithelial ovarian cancers.
    Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31781.
    PubMed         Abstract available

  9. WANG D, Zhu S, Jia C, Cao D, et al
    Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience.
    Gynecol Oncol. 2020 Jan 9. pii: S0090-8258(19)31872.
    PubMed         Abstract available

  10. PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
    Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31870.
    PubMed         Abstract available

  11. RAFFONE A, Travaglino A, Mascolo M, Carotenuto C, et al
    Histopathological characterization of ProMisE molecular groups of endometrial cancer.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30008.
    PubMed         Abstract available

  12. SCOTT SA, Llaurado Fernandez M, Kim H, Elit L, et al
    Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes.
    Gynecol Oncol. 2020;157:36-45.
    PubMed         Abstract available

  13. NASIOUDIS D, Mastroyannis SA, Latif NA, Ko EM, et al
    Trends in the surgical management of malignant ovarian germ-cell tumors.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30087.
    PubMed         Abstract available

  14. NICA A, Lee JYJ, Hong NL, May T, et al
    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.
    Gynecol Oncol. 2020 Oct 6. pii: S0090-8258(20)33961.
    PubMed         Abstract available

  15. UBACHS J, Koole SN, Lahaye M, Fabris C, et al
    No influence of sarcopenia on survival of ovarian cancer patients in a prospective validation study.
    Gynecol Oncol. 2020 Oct 2. pii: S0090-8258(20)33952.
    PubMed         Abstract available

  16. LENTZ SE, Powell CB, Haque R, Armstrong MA, et al
    Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
    Gynecol Oncol. 2020 Oct 1. pii: S0090-8258(20)33914.
    PubMed         Abstract available

  17. KOTSOPOULOS J, Gronwald J, McCuaig JM, Karlan BY, et al
    Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2020 Sep 30. pii: S0090-8258(20)33947.
    PubMed         Abstract available

  18. CHEVROT A, Pouget N, Bats AS, Huchon C, et al
    Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.
    Gynecol Oncol. 2020;157:29-35.
    PubMed         Abstract available

  19. GONTHIER C, Douhnai D, Koskas M
    Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30157.
    PubMed         Abstract available

  20. LENCK C, Chopin N, Gouy S, Bonsang-Kitzis H, et al
    The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
    Gynecol Oncol. 2020 Mar 1. pii: S0090-8258(20)30145.
    PubMed         Abstract available

  21. ROJAS C, Tian C, Powell MA, Chan JK, et al
    Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
    Gynecol Oncol. 2020 Feb 3. pii: S0090-8258(20)30057.
    PubMed         Abstract available

  22. KORENAGA TR, Ward KK, Saenz C, McHale MT, et al
    The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30086.
    PubMed         Abstract available

  23. SIEMON J, Galli J, Slomovitz B, Schlumbrecht M, et al
    Disparities in care among patients with low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(19)31871.
    PubMed         Abstract available

    Int J Cancer

  24. MAJIDI A, Na R, Jordan SJ, De Fazio A, et al
    Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study.
    Int J Cancer. 2020 Oct 9. doi: 10.1002/ijc.33333.
    PubMed         Abstract available

    Int J Gynaecol Obstet

  25. AYHAN A, Akilli H
    Prognostic factors associated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer.
    Int J Gynaecol Obstet. 2020 Oct 6. doi: 10.1002/ijgo.13410.
    PubMed         Abstract available

    PLoS One

  26. FADDA M, Chappuis PO, Katapodi MC, Pagani O, et al
    Physicians communicating with women at genetic risk of breast and ovarian cancer: Are we in the middle of the ford between contradictory messages and unshared decision making?
    PLoS One. 2020;15:e0240054.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.